Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com

Galectin Therapeutics (NASDAQ:GALT) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research note on Tuesday, August 15th.

Galectin Therapeutics Stock Performance

NASDAQ GALT traded down $0.09 during trading on Monday, reaching $1.87. 91,592 shares of the company traded hands, compared to its average volume of 68,072. Galectin Therapeutics has a 1-year low of $1.02 and a 1-year high of $2.47. The stock’s 50 day moving average price is $1.98 and its two-hundred day moving average price is $1.72. The company has a market cap of $115.66 million, a price-to-earnings ratio of -2.46 and a beta of 1.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GALT. Summit Trail Advisors LLC acquired a new stake in Galectin Therapeutics during the 2nd quarter valued at $29,000. Citadel Advisors LLC increased its holdings in Galectin Therapeutics by 269.5% during the 3rd quarter. Citadel Advisors LLC now owns 18,140 shares of the company’s stock valued at $29,000 after purchasing an additional 28,840 shares in the last quarter. Centaurus Financial Inc. acquired a new stake in Galectin Therapeutics during the 1st quarter valued at $34,000. Jane Street Group LLC acquired a new stake in Galectin Therapeutics during the 4th quarter valued at $40,000. Finally, Virtu Financial LLC increased its holdings in Galectin Therapeutics by 205.4% during the 4th quarter. Virtu Financial LLC now owns 39,169 shares of the company’s stock valued at $44,000 after purchasing an additional 26,345 shares in the last quarter. 12.24% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.